SCHEMBL231374

SCHEMBL231374

CC1C2CC3CC(CC1(C(=O)O)C3)C2NC(=O)C(C)(C)N1CCN(c2ccccn2)CC1

nearest known ligand 0.55

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 16/20 0.55
HSD11B2 P80365 4/20 0.55
KDM4E B2RXH2 1/20 0.43
ALDH1A1 P00352 1/20 0.43
HSD17B10 Q99714 1/20 0.43
GRM5 P41594 1/20 0.43
GRM1 Q13255 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2229550 0.92 HSD11B1 (0.46) HSD11B1HSD11B2KDM4EALDH1A1HSD17B10
SCHEMBL2830112 0.86 HSD11B1 (0.75) HSD11B1HSD11B2
SCHEMBL231799 0.84 HSD11B1 (0.46) HSD11B1HSD11B2
SCHEMBL231962 0.84 HSD11B1 (0.72) HSD11B1HSD11B2KDM4EALDH1A1HSD17B10
SCHEMBL233012 0.84 HSD11B1 (0.46) HSD11B1HSD11B2
SCHEMBL230350 0.82 LMNA (0.45) HSD11B1HSD11B2
SCHEMBL15899750 0.80 HSD11B1 (0.55) HSD11B1HSD11B2KDM4EALDH1A1HSD17B10
SCHEMBL232860 0.80 HSD11B1 (0.72) HSD11B1HSD11B2GRM5
SCHEMBL2053330 0.80 HSD11B1 (0.54) HSD11B1HSD11B2KDM4EALDH1A1HSD17B10
SCHEMBL231373 0.79 HSD11B1 (0.60) HSD11B1HSD11B2KDM4EALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2345640-A1 Adamantyl- acetamide derivatives as inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme Abbott Laboratories (US) 2011-07-20 EP claimed
US-20110159005-A1 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11BETA-HSD1) INHIBITORS AND USES THEREOF ABBOTT LABORATORIES (US) 2011-06-30 US claimed
WO-2011068927-A2 11-β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11B-HSD1) INHIBITORS AND USES THEREOF ABBOTT LABORATORIES (US) 2011-06-09 WO claimed
US-7880001-B2 Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme ABBOTT LABORATORIES (US) 2011-02-01 US claimed
US-9464072-B2 Treatment of central nervous system disorders ABBVIE INC. (US) 2016-10-11 US disclosed
US-20150099740-A1 TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS ABBOTT LABORATORIES 2015-04-09 US disclosed
US-20120004206-A1 INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME ABBVIE INC. 2012-01-05 US disclosed
US-20110159005-A1 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11BETA-HSD1) INHIBITORS AND USES THEREOF ABBOTT LABORATORIES (US) 2011-06-30 US disclosed
US-7880001-B2 Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme ABBOTT LABORATORIES (US) 2011-02-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150099740-A1 TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS CHAT, HSD17B1, ACHE HSD11B1 5/4885HSD11B2 14/4885KDM4E 3017/4885
US-20110159005-A1 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11BETA-HSD1) INHIBITORS AND USES THEREOF HSD11B1, HSD17B1, HSD11B2 HSD11B1 1/4885HSD11B2 3/4885KDM4E 3981/4885
US-20120004206-A1 INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME HSD11B1, HSD17B1, HSD11B2 HSD11B1 1/4885HSD11B2 3/4885KDM4E 3313/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.